YHLO (EST. 2008) is an innovative and steadfastly growing company of immunoassay solutions headquartered in Shenzhen, China, specializing in developing, manufacturing, and distributing in-vitro diagnostic instruments and reagents by a team of experienced scientists and engineers.
In May of 2021, YHLO successfully launched IPO and was listed on Shanghai Stock Exchange (Stock code: 688575).
 
To be a reliable and respected IVD enterprise, YHLO has put extensive investments in R&D and is firmly associated with top-tier universities, medical schools, and research institutions worldwide on scientific studies. With over a decade's continuous development expertise in immunoassay solutions, YHLO may provide a broad range of instruments (based on Chemiluminescence, ELISA, Immunoblot, and Immunofluorescence methodologies) with patented technologies and outstanding features, as well as comprehensive total solutions with portfolios in fertility and reproductive health, diabetes, infectious diseases, autoimmune disorders, and other novel assays on rare diseases analysis.